Cruising Review

Adding PEMF to Medications for Diabetic Peripheral Neuropathy


Bemer Review
Comprehensive review of Bemer and PEMF (Pulsed Electromagnetic Field). Explore scientific research, studies, and articles on the benefits and applications of Bemer and PEMF therapy for health and wellness.



Publication Title | Adding PEMF to Medications for Diabetic Peripheral Neuropathy

Health Web PEMF Search Series

Cruising Review Publications search was updated real-time via Filemaker on:

Cruising Review Publications | Return to Search List

Search Completed | Title | Adding PEMF to Medications for Diabetic Peripheral Neuropathy
Original File Name Searched: jlms-11-20.pdf | Google It | Yahoo | Bing


Previous Page | Next Page
adding-pemf-medications-diabetic-peripheral-neuropathy-003</TD> <TD valign=

Page | 003

Shanb et al
had 3 pre-stored programs with different intensity and treatment times. 29
2- The Laser Scanner device (ASA Com. srl, Arcugnano, Italy): It emits a mixed light of both the He-Ne continuous wavelength of 850 nanometers (nm) and the pulsed infrared laser with the wavelength 905 nm. The device had maximum power of 10 watt (W). The output density of the device is calibrated at each applied program and selected frequency.4
Procedures
Assessment Procedure
The following measures were employed for all recruited
patients by a blinded investigator.
a. Fasting Blood Glucose
A venous fasting blood sample was drawn from the anti-cubital vein to detect the blood glucose level (pre- intervention, after 6 weeks and at the end of treatment) for all patients.28
b. Electrophysiological Test
MCV of the peroneal nerve and sensory conduction velocity (SCV) of the sural nerve in addition its amplitudes were measured by a neuro-consultant.22,28 The patients with conduction velocity from 33-48 meter/second were
Table 1. Demographic Data of Recruited Patients
Variables
BMI, kg/ m2
Duration of incidence of diabetes (y) Pre-FBG, mg/dL
Post-FBG, mg/dL
Insulin, No. (%)
Magnetic Group
Mean ± SD
27.32 ± 1.75
16.31 ±7.61 142.38 ±6.8 136.5 ±5.46 5 (19.2)
Laser Group
Mean ± SD
28.17 ± 1.97
18.8 ±7.58 140.68 ±6.77 136.2 ±5.17 4 (16)
Drug Group
Mean ± SD
27.79 ± 1.46
13.65 ± 6.71 141.5 ± 7.01 136.6 ±5.19 4 (20)
F Value
1.493
2.726 0.395 0.062
P Value 0.232
0.073 0.675 0.940
Figure 1. The Flow Diagram of Patients› Recruitment.
Age (y)
60.31 ± 9.82
58.88 ± 12.15
54.05 ±10.69
1.971
0.147
Sex, No. (%)
0.209
0.812
Males
18 (69.3)
16 (64)
12 -- (60)
Females
8 (30.7)
9 (36)
8 -- (40)
Duration of beginning of diabetic neuropathy (y)
4.11 ±2.55
5.0 ±2.71
3.25 ± 2.07
2.767
0.070
in-FBG, mg/dL
136.38 ±5.32
136.08 ±4.99
135.85 ±5.16
0.044
0.957
Oral drugs, No. (%)
21 (80.8)
21 (84)
16 (80)
0.142
0.931
BMI: body mass index; FBG, fasting blood glucose; in-FBG mg/dL: fasting blood glucose after 6 weeks.
22 Journal of Lasers in Medical Sciences Volume 11, Number 1, Winter 2020

Search Contact: greg@cruisingreview.com